nnpNeurology, Neuropsychiatry, PsychosomaticsНеврология, нейропсихиатрия, психосоматика2074-27112310-1342"IMA-Press", LLC10.14412/2074-2711-20214-4-11nnp-1618Research ArticleLECTURESЛЕКЦИЯTreatment of antipsychotic-induced parkinsonism in schizophrenic patientsЛечение антипсихотик-индуцированного паркинсонизма у пациентов с шизофрениейВайманЕ. Э.VaimanE. E.

192019, Санкт-Петербург, ул. Бехтерева, 3.

3, Bekhterev St., Saint Petersburg 192019.

ШнайдерН. А.ShnayderN. A.

192019, Санкт-Петербург, ул. Бехтерева, 3; 660022, Красноярск, ул. Партизана Железняка, 1.

3, Bekhterev St., Saint Petersburg 192019; 1, Partisan Zheleznyak St., Krasnoyarsk 660022.

НезнановН. Г.NeznanovN. G.

192019, Санкт-Петербург, ул. Бехтерева, 3.

3, Bekhterev St., Saint Petersburg 192019.

НасыроваР. Ф.NasyrovaR. F.

Насырова Регина Фаритовна.

192019, Санкт-Петербург, ул. Бехтерева, 3.

3, Bekhterev St., Saint Petersburg 192019.

reginaf@bekhterev.ruНациональный медицинский исследовательский центр психиатрии и неврологии им. В.М. Бехтерева Минздрава РоссииРоссияV.M. Bekhterev National Medical Research Center for Psychiatry and Neurology, Ministry of Health of RussiaRussian FederationНациональный медицинский исследовательский центр психиатрии и неврологии им. В.М. Бехтерева Минздрава России; Красноярский государственный медицинский университет им. проф. В.Ф. Войно-Ясенецкого Минздрава РоссииРоссияV.M. Bekhterev National Medical Research Center for Psychiatry and Neurology, Ministry of Health of Russia; V.F. Voyno-Yasenetsky Krasnoyarsk State Medical UniversityRussian Federation202113082021134411Copyright © Vaiman E.E., Shnayder N.A., Neznanov N.G., Nasyrova R.F., 20212021Вайман Е.Э., Шнайдер Н.А., Незнанов Н.Г., Насырова Р.Ф.Vaiman E.E., Shnayder N.A., Neznanov N.G., Nasyrova R.F.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://nnp.ima-press.net/nnp/article/view/1618

Antipsychotic-induced parkinsonism (AIP) is one of the prognostically unfavorable complications of psychopharmacotherapy in patients with schizophrenia. Many studies have investigated various drugs that are used to treat this neurological side effect. This review analyzes drugs that are used and may be perspective for the treatment of AIP. We searched for full-text publications in Russian and English in the following databases: E-Library, PubMed, Web of Science, Springer, using keywords and combined word searches over the past decade (2011—2020). The review covers drugs that are promising for the correction of AIP, including anticholinergic drugs; NMDA receptor antagonists; dopamine receptor agonists; selective inhibitors of monoamine oxidase B; catecholamine transferase inhibitors; melatonin preparations; melatonin receptor agonists; benzodiazepines; herbal preparations traditionally used for the prevention and correction of extrapyramidal syndrome of various etiologies. Currently, a small number of medications are used in clinical practice for the treatment of AIP. However, not all of them are registered in the Russian Federation. Along with the differences in the mechanisms of AIP pathogenesis in specific patients, the limited choice of AIP treatments makes it difficult to solve the problem of adverse neurological complications of psychopharmacotherapy in schizophrenia.

У пациентов, страдающих шизофренией, антипсихотик-индуцированный паркинсонизм (АИП) является одним из прогностически неблагоприятных осложнений психофармакотерапии. На данный момент проведено немало исследований, изучающих эффективность различных лекарственных средств (ЛС) в отношении лечения этой нежелательной реакции. В обзоре проанализированы ЛС, применяющиеся и перспективные для коррекции АИП. Нами проведен поиск полнотекстовых публикаций на русском и английском языках в базах данных eLIBRARY.RU, PubMed, Web of Science, Springer с использованием ключевых слов и словосочетаний за последнее десятилетие (2011—2020). В обзоре рассмотрены ЛС, перспективные для коррекции АИП, в том числе: антихолинергические препараты; блокаторы глутаматных NMDA-рецепторов; агонисты дофаминовых рецепторов; селективные ингибиторы моноаминоксидазы типа В; ингибиторы катехоламинтрансферазы; препараты мелатонина; агонисты мелатониновых рецепторов; бензодиазепины; препараты растительного происхождения, традиционно применяющиеся для профилактики и коррекции экстрапирамидных синдромов различной этиологии.

В настоящее время в клинической практике применяется небольшие число ЛС для лечения АИП, при этом не все из них зарегистрированы на территории Российской Федерации. Наряду с различиями механизмов патогенеза АИП у конкретных пациентов, ограниченный выбор корректоров АИП затрудняет решение проблемы неблагоприятных неврологических осложнений психофармакотерапии шизофрении.

антипсихотик-индуцированный паркинсонизмболезнь Паркинсоналекарственно-индуцированный паркинсонизмантипсихотикинейролептикитипичные антипсихотикиатипичные антипсихотикилечениеantipsychotic-induced parkinsonismParkinson's diseasedrug-induced parkinsonismantipsychoticsneurolepticstypical antipsychoticsatypical antipsychoticstreatmentReferencesВайман ЕЭ, Шнайдер НА, Незнанов НГ, Насырова РФ. Лекарственно-индуцированный паркинсонизм. Социальная и клиническая психиатрия. 2021;31(1):96-103.Vaiman EE, Schneider NA, Neznanov NG, Nasyrova RF. Drug-induced parkinsonism. Sotsial'naya i klinicheskaya psikhiatriya = Social and clinic psychiatry. 2021;31(1):96-103 (In Russ.).Grunder G, Carlsson A, Wong DF. Mechanism of new antipsychotic medications: occupancy is not just antagonism. Arch Gen Psychiatry. 2003;60(10):974-7. doi: 10.1001/archpsyc.60.10.974Grunder G, Carlsson A, Wong DF. Mechanism of new antipsychotic medications: occupancy is not just antagonism. Arch Gen Psychiatry. 2003;60(10):974-7. doi: 10.1001/archpsyc.60.10.974Scharrer J, Tatsch K, Schwarz J, et al. D2-dopamine receptor occupancy differs between patients with and without extrapyramidal side effects. Acta Psychiatr Scand. 1994 Oct;90(4):266-8. doi: 10.1111/j.1600-0447.1994.tb01591.xScharrer J, Tatsch K, Schwarz J, et al. D2-dopamine receptor occupancy differs between patients with and without extrapyramidal side effects. Acta Psychiatr Scand. 1994 Oct;90(4):266-8. doi: 10.1111/j.1600-0447.1994.tb01591.xAl Hadithy AF, Wilffert B, Bruggeman R, et al. Lack of association between antipsychotic-induced Parkinsonism or its subsymptoms and rs4606 SNP of RGS2 gene in African-Caribbeans and the possible role of the medication: the Curacao extrapyramidal syndromes study X. Hum Psychopharmacol. 2009;24(2):123-8. doi: 10.1002/hup.997Al Hadithy AF, Wilffert B, Bruggeman R, et al. Lack of association between antipsychotic-induced Parkinsonism or its subsymptoms and rs4606 SNP of RGS2 gene in African-Caribbeans and the possible role of the medication: the Curacao extrapyramidal syndromes study X. Hum Psychopharmacol. 2009;24(2):123-8. doi: 10.1002/hup.997Bakker PR, Bakker E, Amin N, et al. Candidate gene-based association study of antipsychotic-induced movement disorders in long-stay psychiatric patients: a prospective study. PLoS One. 2012;7(5):e36561. doi: 10.1371/journal.pone.0036561Bakker PR, Bakker E, Amin N, et al. Candidate gene-based association study of antipsychotic-induced movement disorders in long-stay psychiatric patients: a prospective study. PLoS One. 2012;7(5):e36561. doi: 10.1371/journal.pone.0036561Вайман ЕЭ, Шнайдер НА, Незнанов НГ, Насырова РФ. Методы диагностики лекарственно-индуцированного паркинсонизма: обзор отечественной и зарубежной литературы. Сибирский вестник психиатрии и наркологии. 2020;4(109):64-72. doi: 10.26617/1810-3111-2020-4(109)-64-72Vaiman EE, Schneider NA, Neznanov NG, Nasyrova RF. Diagnostic methods for drug-induced parkinsonism: a review of Russian and foreign literature. Sibirskiy vestnik psikhia-trii i narkologii = Siberian Herald of Psychiatry and Addiction Psychiatry. 2020;4(109):64-72. doi: 10.26617/1810-3111-2020-4(109)-64-72 (In Russ.).Mamo DC, Sweet RA, Keshavan MS. Managing antipsychotic-induced parkinsonism. Drug Saf. 1999 Mar;20(3):269-75. doi: 10.2165/00002018-199920030-00006Mamo DC, Sweet RA, Keshavan MS. Managing antipsychotic-induced parkinsonism. Drug Saf. 1999 Mar;20(3):269-75. doi: 10.2165/00002018-199920030-00006Kapur S, Seeman P. Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry. 2001;158:360-9. doi: 10.1176/appi.ajp.158.3.360Kapur S, Seeman P. Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry. 2001;158:360-9. doi: 10.1176/appi.ajp.158.3.360Ward KM, Citrome L. Antipsychotic-Related Movement Disorders: Drug-Induced Parkinsonism vs. Tardive Dyskinesia-Key Differences in Pathophysiology and Clinical Management. Neurol Ther. 2018;7(2):233-48. doi: 10.1007/s40120-018-0105-0Ward KM, Citrome L. Antipsychotic-Related Movement Disorders: Drug-Induced Parkinsonism vs. Tardive Dyskinesia-Key Differences in Pathophysiology and Clinical Management. Neurol Ther. 2018;7(2):233-48. doi: 10.1007/s40120-018-0105-0Branchey MH, Branchey LB, Richardson MAR. Effects of neuroleptic adjustment on clinical condition and tardive dyskinesia in schizophrenic patients. Am J Psychiatry. 1981 May;138(5):608-12. doi: 10.1176/ajp.138.5.608Branchey MH, Branchey LB, Richardson MAR. Effects of neuroleptic adjustment on clinical condition and tardive dyskinesia in schizophrenic patients. Am J Psychiatry. 1981 May;138(5):608-12. doi: 10.1176/ajp.138.5.608Shapiro AK. Psychochemotherapy. In: Grenell RO, Gabay S, editors. Biological foundations of psychiatry. New York: Raven Press; 1971. P. 793-840.Shapiro AK. Psychochemotherapy. In: Grenell RO, Gabay S, editors. Biological foundations of psychiatry. New York: Raven Press; 1971. P. 793-840.Miller R. Dose-response relationships for the antipsychotic effects and parkinsonian side-effects of typical neuroleptic drugs: practical and theoretical implications. Prog Neuropsychopharmacol Biol Psychiatry. 1997 Oct;21(7):1059-94. doi: 10.1016/s0278-5846(97)00099-7Miller R. Dose-response relationships for the antipsychotic effects and parkinsonian side-effects of typical neuroleptic drugs: practical and theoretical implications. Prog Neuropsychopharmacol Biol Psychiatry. 1997 Oct;21(7):1059-94. doi: 10.1016/s0278-5846(97)00099-7Pierre J. Extrapyramidal symptoms with atypical antipsychotics. Incidence, prevention and management. Drug Saf. 2005;28(3):191-208. doi: 10.2165/00002018-200528030-00002Pierre J. Extrapyramidal symptoms with atypical antipsychotics. Incidence, prevention and management. Drug Saf. 2005;28(3):191-208. doi: 10.2165/00002018-200528030-00002Насырова РФ, Незнанов НГ, редакторы. Клиническая психофармакогенетика. Санкт-Петербург: Издательство ДЕАН; 2019. 405 с.Nasyrova RF, Neznanov NG, editors. Klinicheskaya psikhofarmakogenetika [Clinical psychopharmacogenetics]. St. Petersburg: DEAN Publishing House; 2019. 405 p. (In Russ.).Насырова РФ, Шнайдер НА, Миронов КО и др. Фармакогенетика шизофрении в реальной клинической практике: клинический случай. Неврология, нейропсихиатрия, психосоматика. 2018;10(4):88-93. doi: 10.14412/2074-2711-2018-4-88-93Nasyrova RF, Schnaider NA, Mironov KO, et al. Pharmacogenetics of schizophrenia in real clinical practice: a clinical case. Nevrologiya, neyropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2018;10(4):88-93. doi: 10.14412/2074-2711-2018-4-88-93 (In Russ.).Haase HJ. Clinical observations on the actions of neuroleptics. In: Haase HJ, Janssen PA, editors. The actions of neuroleptic drugs: a psychiatric, neurological, and pharmacological investigation. Amsterdam: N Holland; 1965. P. 1-98.Haase HJ. Clinical observations on the actions of neuroleptics. In: Haase HJ, Janssen PA, editors. The actions of neuroleptic drugs: a psychiatric, neurological, and pharmacological investigation. Amsterdam: N Holland; 1965. P. 1-98.Singh M. Therapeutic reversal with benztropine in schizophrenia. J Nerv Ment Dis. 1975 Apr;160(4):258-66. doi: 10.1097/00005053-197504000-00005Singh M. Therapeutic reversal with benztropine in schizophrenia. J Nerv Ment Dis. 1975 Apr;160(4):258-66. doi: 10.1097/00005053-197504000-00005Johnston EC, Crow TJ, Ferrier IN, et al. Adverse effects of anticholinergic medication on positive schizophrenic symptoms. Psychol Med. 1983 Aug;13(3):513-27. doi: 10.1017/s0033291700047942Johnston EC, Crow TJ, Ferrier IN, et al. Adverse effects of anticholinergic medication on positive schizophrenic symptoms. Psychol Med. 1983 Aug;13(3):513-27. doi: 10.1017/s0033291700047942Kane JM, Woerner M, Borenstein M, et al. Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacol Bull. 1986;22(1):254-9.Kane JM, Woerner M, Borenstein M, et al. Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacol Bull. 1986;22(1):254-9.Ungvari GS, Chiu HFK, Lam LCW, et al. Gradual withdrawal of long-term anticholinergic antiparkinsonian medication in Chinese patients with chronic schizophrenia. J Clin Psychopharmacol. 1999 Apr;19(2):141-8. doi: 10.1097/00004714-199904000-00009Ungvari GS, Chiu HFK, Lam LCW, et al. Gradual withdrawal of long-term anticholinergic antiparkinsonian medication in Chinese patients with chronic schizophrenia. J Clin Psychopharmacol. 1999 Apr;19(2):141-8. doi: 10.1097/00004714-199904000-00009Caligiuri MR, Jeste DV, Lacro JP. Antipsychotic-induced movement disorders in the elderly: epidemiology and treatment recommendations. Drugs Aging. 2000;17(5):363-84. doi: 10.2165/00002512-200017050-00004Caligiuri MR, Jeste DV, Lacro JP. Antipsychotic-induced movement disorders in the elderly: epidemiology and treatment recommendations. Drugs Aging. 2000;17(5):363-84. doi: 10.2165/00002512-200017050-00004Di Mascio A, Bernardo DL, Greenblatt DJ, et al. A controlled trial of amantadine in drug-induced extrapyramidal disorders. Arch Gen Psychiatry. 1976 May;33(5):599-602. doi: 10.1001/archpsyc.1976.01770050055008Di Mascio A, Bernardo DL, Greenblatt DJ, et al. A controlled trial of amantadine in drug-induced extrapyramidal disorders. Arch Gen Psychiatry. 1976 May;33(5):599-602. doi: 10.1001/archpsyc.1976.01770050055008Aoki F, Sitar D. Clinical pharmacokinetics of amantadine hydrochloride. Clin Pharmacokinet. 1988 Jan;14(1):35-51. doi: 10.2165/00003088-198814010-00003Aoki F, Sitar D. Clinical pharmacokinetics of amantadine hydrochloride. Clin Pharmacokinet. 1988 Jan;14(1):35-51. doi: 10.2165/00003088-198814010-00003Gianutsos G, Stewart C, Dunn JP. Pharmacologic changes in dopaminergic systems induced by long-term administration of amantadine. Eur J Pharmacol. 1985 Apr 16;110(3):357-61. doi: 10.1016/0014-2999(85)90564-3Gianutsos G, Stewart C, Dunn JP. Pharmacologic changes in dopaminergic systems induced by long-term administration of amantadine. Eur J Pharmacol. 1985 Apr 16;110(3):357-61. doi: 10.1016/0014-2999(85)90564-3Yadalam KG. Drug-induced parkinsonism. In: Keshavan MS, Kennedy JS, editors. Drug-induced dysfunction in psychiatry. New York: Hemisphere Publishing Corporation; 1992. P. 119-29.Yadalam KG. Drug-induced parkinsonism. In: Keshavan MS, Kennedy JS, editors. Drug-induced dysfunction in psychiatry. New York: Hemisphere Publishing Corporation; 1992. P. 119-29.Yaryura-Tobias JA, Wolpert A, Dana L, et al. Action of L-dopa in drug induced extrapyramidalism. Dis Nerv Syst. 1970 Jan;31(1):60-3.Yaryura-Tobias JA, Wolpert A, Dana L, et al. Action of L-dopa in drug induced extrapyramidalism. Dis Nerv Syst. 1970 Jan;31(1):60-3.Rajput A, Rozdilsky B, Hornykiewicz O, et al. Reversible drug induced parkinsonism: clinicopathologic study of two cases. Arch Neurol. 1982 Oct;39(10):644-6. doi: 10.1001/archneur.1982.00510220042009Rajput A, Rozdilsky B, Hornykiewicz O, et al. Reversible drug induced parkinsonism: clinicopathologic study of two cases. Arch Neurol. 1982 Oct;39(10):644-6. doi: 10.1001/archneur.1982.00510220042009Di Fabio R, De Filippis S, Cafariello C, et al. Low doses of rotigotine in patients with antipsychotic-induced parkinsonism. Clin Neuropharmacol. 2013;36(5):162-5. doi: 10.1097/WNF.0b013e3182a2ce3fDi Fabio R, De Filippis S, Cafariello C, et al. Low doses of rotigotine in patients with antipsychotic-induced parkinsonism. Clin Neuropharmacol. 2013;36(5):162-5. doi: 10.1097/WNF.0b013e3182a2ce3fWeng JJ, Wang LH, Zhu H, et al. Efficacy of low-dose D2/D3 partial agonist pramipexole on neuroleptic-induced extrapyramidal symptoms and symptoms of schizophrenia: a stage-1 open-label pilot study. Neuropsychiatr Dis Treat. 2019 Aug 7;15:2195-203. doi: 10.2147/NDT.S205933. eCollection 2019.Weng JJ, Wang LH, Zhu H, et al. Efficacy of low-dose D2/D3 partial agonist pramipexole on neuroleptic-induced extrapyramidal symptoms and symptoms of schizophrenia: a stage-1 open-label pilot study. Neuropsychiatr Dis Treat. 2019 Aug 7;15:2195-203. doi: 10.2147/NDT.S205933. eCollection 2019.Simon N, Micallef J, Reynier JC, et al. End-of-dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients: a pharmacoki-netic/pharmacodynamic, randomized, doubleblind study. Mov Disord. 2005;20(7):803-9. doi: 10.1002/mds.20400Simon N, Micallef J, Reynier JC, et al. End-of-dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients: a pharmacoki-netic/pharmacodynamic, randomized, doubleblind study. Mov Disord. 2005;20(7):803-9. doi: 10.1002/mds.20400Perez-Lloret S, Rascol O. Piribedil for the Treatment of Motor and Non-motor Symptoms of Parkinson Disease. CNS Drugs. 2016;30(8):703-17. doi: 10.1007/s40263-016-0360-5Perez-Lloret S, Rascol O. Piribedil for the Treatment of Motor and Non-motor Symptoms of Parkinson Disease. CNS Drugs. 2016;30(8):703-17. doi: 10.1007/s40263-016-0360-5VIDAL. Available from: https://www.vidal.ru/drugs/molecule/2081 (accessed 13.04.2021).VIDAL. Available from: https://www.vidal.ru/drugs/molecule/2081 (accessed 13.04.2021).Вербицкий ЕВ. Психотропные свойства препаратов мелатонина в эксперименте и клинике. Эффективная фармакотерапия. 2019;15(44):32-40. doi: 10.33978/2307-35862019-15-44-32-40Verbitsky EV. Psychotropic properties of melatonin drugs in experiment and clinic. Effektivnaya farmakoterapiya = Effective Pharmacotherapy. 2019;15(44):32-40. doi: 10.33978/2307-3586-2019-15-44-32-40 (In Russ.).Sood S. Melatonin and sleep in schizophrenia: a commentary. Sleep Med Dis Int J. 2018;2(4):93-4. doi: 10.15406/smdij.2018.02.00049Sood S. Melatonin and sleep in schizophrenia: a commentary. Sleep Med Dis Int J. 2018;2(4):93-4. doi: 10.15406/smdij.2018.02.00049Anderson G, Maes M. Melatonin: an overlooked factor in schizophrenia and in the inhibition of anti-psychotic side effects. Metab Brain Dis. 2012;27(2):113-9. doi: 10.1007/s11011-012-9307-9Anderson G, Maes M. Melatonin: an overlooked factor in schizophrenia and in the inhibition of anti-psychotic side effects. Metab Brain Dis. 2012;27(2):113-9. doi: 10.1007/s11011-012-9307-9Morera-Fumero AL, Abreu-Gonzalez P. Role of melatonin in schizophrenia. Int J Mol Sci. 2013;14(5):9037-50. doi: 10.3390/ijms14059037Morera-Fumero AL, Abreu-Gonzalez P. Role of melatonin in schizophrenia. Int J Mol Sci. 2013;14(5):9037-50. doi: 10.3390/ijms14059037Gobbi G, Comai S. Differential function of melatonin MT1 and MT2 receptors in REM and NREM sleep. Front Endocrinol. 2019 Mar 1;10:87. doi: 10.3389/fendo.2019.00087. eCollection 2019.Gobbi G, Comai S. Differential function of melatonin MT1 and MT2 receptors in REM and NREM sleep. Front Endocrinol. 2019 Mar 1;10:87. doi: 10.3389/fendo.2019.00087. eCollection 2019.Mutschler J, Rusch N, Schonfelder H, et al. Agomelatine for Depression in Schizophrenia: A Case-Series. Psychopharmacol Bull. 2012 Feb 15;45(1):35-43.Mutschler J, Rusch N, Schonfelder H, et al. Agomelatine for Depression in Schizophrenia: A Case-Series. Psychopharmacol Bull. 2012 Feb 15;45(1):35-43.Englisch S, Jung HS, Eisenacher S, et al. Neurocognitive Effects of Agomelatine Treatment in Schizophrenia Patients Suffering From Comorbid Depression: Results From the AGOPSYCH Study. J Clin Psychopharmacol. 2018;38(4):357-61. doi: 10.1097/JCP.0000000000000909Englisch S, Jung HS, Eisenacher S, et al. Neurocognitive Effects of Agomelatine Treatment in Schizophrenia Patients Suffering From Comorbid Depression: Results From the AGOPSYCH Study. J Clin Psychopharmacol. 2018;38(4):357-61. doi: 10.1097/JCP.0000000000000909Mishra A, Maiti R, Mishra BR, et al. Effect of add-on ramelteon therapy on sleep and circadian rhythm disruption in patients with schizophrenia: A randomized controlled trial. Eur Neuropsychopharmacol. 2020;31:109-18. doi: 10.1016/j.euroneuro.2019.11.008Mishra A, Maiti R, Mishra BR, et al. Effect of add-on ramelteon therapy on sleep and circadian rhythm disruption in patients with schizophrenia: A randomized controlled trial. Eur Neuropsychopharmacol. 2020;31:109-18. doi: 10.1016/j.euroneuro.2019.11.008Hatta K, Kishi Y, Wada K, et al. Real-World Effectiveness of Ramelteon and Suvorexant for Delirium Prevention in 948 Patients With Delirium Risk Factors. J Clin Psychiatry. 2019 Dec 17;81(1):19m12865. doi: 10.4088/JCP.19m12865Hatta K, Kishi Y, Wada K, et al. Real-World Effectiveness of Ramelteon and Suvorexant for Delirium Prevention in 948 Patients With Delirium Risk Factors. J Clin Psychiatry. 2019 Dec 17;81(1):19m12865. doi: 10.4088/JCP.19m12865Skelton RL, Kornhauser JM, Tate BA. Personalized medicine for pathological circadian dysfunctions. Front Pharmacol. 2015 Jun 19;6:125. doi: 10.3389/fphar.2015.00125. eCollection 2015.Skelton RL, Kornhauser JM, Tate BA. Personalized medicine for pathological circadian dysfunctions. Front Pharmacol. 2015 Jun 19;6:125. doi: 10.3389/fphar.2015.00125. eCollection 2015.Laudon М, Frydman-Marom A. Therapeutic effects of melatonin receptor agonists on sleep and comorbid disorders. Int J Mol Sci. 2014 Sep 9;15(9):15924-50. doi: 10.3390/ijms150915924Laudon М, Frydman-Marom A. Therapeutic effects of melatonin receptor agonists on sleep and comorbid disorders. Int J Mol Sci. 2014 Sep 9;15(9):15924-50. doi: 10.3390/ijms150915924Spadoni G, Bedim A, Rivara S, Mor М. Melatonin receptor agonists: new options for insomnia and depression treatment. CNS Neurosci Ther. 2011;17(6):733-41. doi: 10.1111/j.1755-5949.2010.00197.xSpadoni G, Bedim A, Rivara S, Mor М. Melatonin receptor agonists: new options for insomnia and depression treatment. CNS Neurosci Ther. 2011;17(6):733-41. doi: 10.1111/j.1755-5949.2010.00197.xFarver DK, Khan МН. Zolpidem for antipsychotic-induced parkinsonism. Ann Pharmacother. 2001;35(4):435-7. doi: 10.1345/aph.10214Farver DK, Khan МН. Zolpidem for antipsychotic-induced parkinsonism. Ann Pharmacother. 2001;35(4):435-7. doi: 10.1345/aph.10214Daniele A, Albanese A, Gainotti G, et al. Zolpidem in Parkinson's disease. Lancet. 1997 Apr 26;349(9060):1222-3. doi: 10.1016/S0140-6736(05)62416-6Daniele A, Albanese A, Gainotti G, et al. Zolpidem in Parkinson's disease. Lancet. 1997 Apr 26;349(9060):1222-3. doi: 10.1016/S0140-6736(05)62416-6Lloyd GK, Lowenthal A, Javoy-Agid F, Constantidinis J. GABAA receptor complex function in frontal cortex membranes from control and neurological patients. Eur J Pharmacol. 1991 Мяу 2;197(1):33-9. doi: 10.1016/0014-2999(91)90361-sLloyd GK, Lowenthal A, Javoy-Agid F, Constantidinis J. GABAA receptor complex function in frontal cortex membranes from control and neurological patients. Eur J Pharmacol. 1991 Мяу 2;197(1):33-9. doi: 10.1016/0014-2999(91)90361-sGeoffrey YMW, Tarun B, Rohan D. Potential antipsychotic effects of zolpidem. Aust N Z J Psychiatry. 2010 Feb;44(2):190. doi: 10.3109/00048670903487290Geoffrey YMW, Tarun B, Rohan D. Potential antipsychotic effects of zolpidem. Aust N Z J Psychiatry. 2010 Feb;44(2):190. doi: 10.3109/00048670903487290Eslami-Shahrbabaki М, Barfeh B, Nasirian М. Persistent psychosis after abuse of high dose of zolpidem. Addict Health. Summer-Autumn 2014;6(3-4):159-62.Eslami-Shahrbabaki М, Barfeh B, Nasirian М. Persistent psychosis after abuse of high dose of zolpidem. Addict Health. Summer-Autumn 2014;6(3-4):159-62.Saint-Clair Bahls. tolerance to zolpidem-induced hallucinations: case report. Rev Psiquiatr Rio Gd Sul. 2005;27(3):319-22. doi: 10.1590/S0101-81082005000300011Saint-Clair Bahls. tolerance to zolpidem-induced hallucinations: case report. Rev Psiquiatr Rio Gd Sul. 2005;27(3):319-22. doi: 10.1590/S0101-81082005000300011Stummer L, Markovic М, Maroney МЕ. Pharmacologic Treatment Options for Insomnia in Patients with Schizophrenia. Medicines (Basel). 2018;5(3):88. doi: 10.3390/medicines5030088Stummer L, Markovic М, Maroney МЕ. Pharmacologic Treatment Options for Insomnia in Patients with Schizophrenia. Medicines (Basel). 2018;5(3):88. doi: 10.3390/medicines5030088Ferentinos P, Paparrigopoulos Т. Zopiclone and sleepwalking. Int J Neuropsychopharmacol. 2009;12(1):141-2. doi: 10.1017/S1461145708009541Ferentinos P, Paparrigopoulos Т. Zopiclone and sleepwalking. Int J Neuropsychopharmacol. 2009;12(1):141-2. doi: 10.1017/S1461145708009541Kajimura N, Kato М, Okuma Т, Onuma Т. Effects of zopiclone on sleep and symptoms in schizophrenia: comparison with benzodiazepine hypnotics. Prog Neuropsychopharmacol Biol Psychiatry. 1994;18(3):477-90. doi: 10.1016/0278-5846(94)90005-1Kajimura N, Kato М, Okuma Т, Onuma Т. Effects of zopiclone on sleep and symptoms in schizophrenia: comparison with benzodiazepine hypnotics. Prog Neuropsychopharmacol Biol Psychiatry. 1994;18(3):477-90. doi: 10.1016/0278-5846(94)90005-1Diaz GA, Costanzo МС, Rosas МЕ, Arroyo MB. Sleep Disorders in Schizophrenia. A Review of Literature. Theranostics Brain Spine Neural Disord. 2017;1(5):555575. doi: 10.19080/rBSND.2017.01.555575Diaz GA, Costanzo МС, Rosas МЕ, Arroyo MB. Sleep Disorders in Schizophrenia. A Review of Literature. Theranostics Brain Spine Neural Disord. 2017;1(5):555575. doi: 10.19080/rBSND.2017.01.555575

The authors declare that there are no conflicts of interest present.